drugset
drugset / Trial / NCT06076291

An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors

NCT06076291 ↗

Phase 1 Active not recruiting 122 enrolled Hangzhou Sumgen Biotech Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase I, open-label, dose escalation and dose expansion study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SG1827 in subjects with Advanced Solid Tumors, refractory or resistant to standard therapy, or without available standard or curative therapy.

Timeline

Start
2023-09-27
Primary completion
2026-03-18
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject SG1827 Unknown 0.02 mg/kg Intravenous
Subject SG1827 Unknown 0.2 mg/kg Intravenous
Subject SG1827 Unknown 1 mg/kg Intravenous
Subject SG1827 Unknown 3 mg/kg Intravenous
Subject SG1827 Unknown 6 mg/kg Intravenous
Subject SG1827 Unknown 10 mg/kg Intravenous
Subject SG1827 Unknown 15 mg/kg Intravenous

Indications

cancer